Ivana Barravecchia
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ivana Barravecchia has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Brian Magnuson
University of Michigan
22 shared publications - Carlos E. Espinoza
Department of Surgery, the University of Michigan Medical School, Ann Arbor, Michigan
22 shared publications - Stefanie Galban
Center for Molecular Imaging, The University of Michigan Medical School, Ann Arbor, Michigan
22 shared publications - Craig J. Galban
University of Michigan
13 shared publications - Jason Manassa
Department of Materials Science and Engineering, University of Michigan 2 , Ann Arbor, Michigan 48109
13 shared publications - Jennifer M. Lee
Center for Molecular Imaging, The University of Michigan Medical School, Ann Arbor, Michigan
13 shared publications
Latest Publications
- Open Access
- 1 March 2024
- Published by American Association for Cancer Research (AACR)
Supplemental Table S2 from Modeling Molecular Pathogenesis of Idiopathic Pulmonary Fibrosis-Associated Lung Cancer in Mice
Supplemental Table S2. Antibody panel used for CyTOF analysis.
- 1 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table S2 from Modeling Molecular Pathogenesis of Idiopathic Pulmonary Fibrosis-Associated Lung Cancer in Mice
Supplemental Table S2. Antibody panel used for CyTOF analysis.
- Open Access
- 1 March 2024
- Published by American Association for Cancer Research (AACR)
Supplemental Table S1 from Modeling Molecular Pathogenesis of Idiopathic Pulmonary Fibrosis-Associated Lung Cancer in Mice
Supplemental Table S1. Stains and antibodies used for mIHC.
- 1 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table S1 from Modeling Molecular Pathogenesis of Idiopathic Pulmonary Fibrosis-Associated Lung Cancer in Mice
Supplemental Table S1. Stains and antibodies used for mIHC.
- Open Access
- 1 March 2024
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S3 from Modeling Molecular Pathogenesis of Idiopathic Pulmonary Fibrosis-Associated Lung Cancer in Mice
Supplemental Figure S3. PCA biplot (PC1 and PC2) of VST-normalized gene counts for the top 500 most variable genes.
- 1 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S3 from Modeling Molecular Pathogenesis of Idiopathic Pulmonary Fibrosis-Associated Lung Cancer in Mice
Supplemental Figure S3. PCA biplot (PC1 and PC2) of VST-normalized gene counts for the top 500 most variable genes.
- Open Access
- 1 March 2024
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S2 from Modeling Molecular Pathogenesis of Idiopathic Pulmonary Fibrosis-Associated Lung Cancer in Mice
Supplemental Figure S2. Expression of immune cell surface markers by CyTOF.
- 1 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S2 from Modeling Molecular Pathogenesis of Idiopathic Pulmonary Fibrosis-Associated Lung Cancer in Mice
Supplemental Figure S2. Expression of immune cell surface markers by CyTOF.
- Open Access
- 1 March 2024
- Published by American Association for Cancer Research (AACR)
Data from Modeling Molecular Pathogenesis of Idiopathic Pulmonary Fibrosis-Associated Lung Cancer in Mice
Idiopathic pulmonary fibrosis (IPF) is characterized by progressive, often fatal loss of lung function due to overactive collagen production and tissue scarring. Patients with IPF have a sevenfold-increased risk of developing lung cancer. The COVID-19 pandemic has increased the number of patients with lung diseases, and infection can worsen prognoses for those with chronic lung diseases and disease-associated cancer. Understanding the molecular pathogenesis of IPF-associated lung cancer is imperative for identifying diagnostic biomarkers and targeted therapies that will facilitate prevention of IPF and progression to lung cancer. To understand how IPF-associated fibroblast activation, matrix remodeling, epithelial-to-mesenchymal transition (EMT), and immune modulation influences lung cancer predisposition, we developed a mouse model to recapitulate the molecular pathogenesis of pulmonary fibrosis–associated lung cancer using the bleomycin and Lewis lung carcinoma models. We demonstrate that development of pulmonary fibrosis–associated lung cancer is likely linked to increased abundance of tumor-associated macrophages and a unique gene signature that supports an immune-suppressive microenvironment through secreted factors. Not surprisingly, preexisting fibrosis provides a pre-metastatic niche and results in augmented tumor growth, and tumors associated with bleomycin-induced fibrosis are characterized by a dramatic loss of cytokeratin expression, indicative of EMT.Implications:This characterization of tumors associated with lung diseases provides new therapeutic targets that may aid in the development of treatment paradigms for lung cancer patients with preexisting pulmonary diseases.
- 1 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from Modeling Molecular Pathogenesis of Idiopathic Pulmonary Fibrosis-Associated Lung Cancer in Mice
Idiopathic pulmonary fibrosis (IPF) is characterized by progressive, often fatal loss of lung function due to overactive collagen production and tissue scarring. Patients with IPF have a sevenfold-increased risk of developing lung cancer. The COVID-19 pandemic has increased the number of patients with lung diseases, and infection can worsen prognoses for those with chronic lung diseases and disease-associated cancer. Understanding the molecular pathogenesis of IPF-associated lung cancer is imperative for identifying diagnostic biomarkers and targeted therapies that will facilitate prevention of IPF and progression to lung cancer. To understand how IPF-associated fibroblast activation, matrix remodeling, epithelial-to-mesenchymal transition (EMT), and immune modulation influences lung cancer predisposition, we developed a mouse model to recapitulate the molecular pathogenesis of pulmonary fibrosis–associated lung cancer using the bleomycin and Lewis lung carcinoma models. We demonstrate that development of pulmonary fibrosis–associated lung cancer is likely linked to increased abundance of tumor-associated macrophages and a unique gene signature that supports an immune-suppressive microenvironment through secreted factors. Not surprisingly, preexisting fibrosis provides a pre-metastatic niche and results in augmented tumor growth, and tumors associated with bleomycin-induced fibrosis are characterized by a dramatic loss of cytokeratin expression, indicative of EMT.Implications:This characterization of tumors associated with lung diseases provides new therapeutic targets that may aid in the development of treatment paradigms for lung cancer patients with preexisting pulmonary diseases.
- Open Access
- 1 March 2024
- Published by American Association for Cancer Research (AACR)
Supplemental Table S1 from Modeling Molecular Pathogenesis of Idiopathic Pulmonary Fibrosis-Associated Lung Cancer in Mice
Supplemental Table S1. Stains and antibodies used for mIHC.
- 1 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table S1 from Modeling Molecular Pathogenesis of Idiopathic Pulmonary Fibrosis-Associated Lung Cancer in Mice
Supplemental Table S1. Stains and antibodies used for mIHC.
- Open Access
- 1 March 2024
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S1 from Modeling Molecular Pathogenesis of Idiopathic Pulmonary Fibrosis-Associated Lung Cancer in Mice
Supplemental Figure S1. Transgenic mouse IPF-LC model development.
- 1 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S1 from Modeling Molecular Pathogenesis of Idiopathic Pulmonary Fibrosis-Associated Lung Cancer in Mice
Supplemental Figure S1. Transgenic mouse IPF-LC model development.
- Open Access
- 1 March 2024
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S3 from Modeling Molecular Pathogenesis of Idiopathic Pulmonary Fibrosis-Associated Lung Cancer in Mice
Supplemental Figure S3. PCA biplot (PC1 and PC2) of VST-normalized gene counts for the top 500 most variable genes.
- 1 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S3 from Modeling Molecular Pathogenesis of Idiopathic Pulmonary Fibrosis-Associated Lung Cancer in Mice
Supplemental Figure S3. PCA biplot (PC1 and PC2) of VST-normalized gene counts for the top 500 most variable genes.
- Open Access
- 1 March 2024
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S2 from Modeling Molecular Pathogenesis of Idiopathic Pulmonary Fibrosis-Associated Lung Cancer in Mice
Supplemental Figure S2. Expression of immune cell surface markers by CyTOF.
- 1 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S2 from Modeling Molecular Pathogenesis of Idiopathic Pulmonary Fibrosis-Associated Lung Cancer in Mice
Supplemental Figure S2. Expression of immune cell surface markers by CyTOF.
- Open Access
- 1 March 2024
- Published by American Association for Cancer Research (AACR)
Supplemental Table S2 from Modeling Molecular Pathogenesis of Idiopathic Pulmonary Fibrosis-Associated Lung Cancer in Mice
Supplemental Table S2. Antibody panel used for CyTOF analysis.
- 1 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table S2 from Modeling Molecular Pathogenesis of Idiopathic Pulmonary Fibrosis-Associated Lung Cancer in Mice
Supplemental Table S2. Antibody panel used for CyTOF analysis.